在初级中枢神经系统淋巴瘤的目标和治疗方法
Christina von Roemeling1, Andrés J M Ferreri2,3, Carole Soussain4,5
1Preston A. Wells Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
Leukemia & lymphoma
|April 25, 2024
概括
初级中枢神经系统淋巴瘤 (PCNSL) 是一种侵袭性脑癌. 向疗法,包括布鲁顿的氨酸激酶 (BTK) 抑制剂,在治疗复发性或耐火性PCNSL方面表现有前途.
科学领域:
- 神经瘤学神经瘤学
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 初级中枢神经系统淋巴瘤 (PCNSL) 是一种罕见的,侵略性的恶性瘤,仅限于中枢神经系统.
- 虽然PCNSL最初对基于甲醇的化疗有反应,但复发或耐火性 (R/R) PCNSL的预后不佳.
- PCNSL的发病包括通过B细胞受体 (BCR) 或通道类似受体 (TLR) 信号的核因子kappa B (NF-κB) 途径激活,以及免疫逃避机制.
研究的目的:
- 审查目前的证据和针对性治疗药物的潜力,以改善PCNSL的治疗结果.
- 探索用于PCNSL管理的免疫治疗,免疫调节和特定途径抑制剂.
主要方法:
- 在PCNSL中针对性治疗的文献综述.
- 对新型药物的临床前和临床数据的分析.
- 专注于针对BCR和TLR等关键信号通路的抑制剂.
主要成果:
- 布鲁顿的氨酸激酶 (BTK) 抑制剂,针对下游BCR激活,已在R/R PCNSL中显示出有希望的疗效.
- 向性药物提供了超越传统化疗的新治疗途径.
结论:
- 向疗法在治疗R/R PCNSL方面取得了重大进展.
- 抑制关键通路,如BCR和TLR信号传输,有可能成为未来的PCNSL治疗策略.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy
520
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520


